Division of Nephrology, Department of Medicine, Box 103015, Duke University Medical Center, Durham, NC 27710, USA.
Hypertension. 2010 Jan;55(1):99-108. doi: 10.1161/HYPERTENSIONAHA.109.144964. Epub 2009 Dec 7.
Activation of type 1 angiotensin (AT(1)) receptors causes hypertension, leading to progressive kidney injury. AT(1) receptors are expressed on immune cells, and previous studies have identified a role for immune cells in angiotensin II-dependent hypertension. We, therefore, examined the role of AT(1) receptors on immune cells in the pathogenesis of hypertension by generating bone marrow chimeras with wild-type donors or donors lacking AT(1A) receptors (BMKO). The 2 groups had virtually identical blood pressures at baseline, suggesting that AT(1) receptors on immune cells do not make a unique contribution to the determination of baseline blood pressure. By contrast, in response to chronic angiotensin II infusion, the BMKOs had an augmented hypertensive response, suggesting a protective effect of AT(1) receptors on immune cells with respect to blood pressure elevation. The BMKOs had 50% more albuminuria after 4 weeks of angiotensin II-dependent hypertension. Angiotensin II-induced pathological injury to the kidney was similar in the experimental groups. However, there was exaggerated renal expression of the macrophage chemokine monocyte chemoattractant protein 1 in the BMKO group, leading to persistent accumulation of macrophages in the kidney. This enhanced mononuclear cell infiltration into the BMKO kidneys was associated with exaggerated renal expression of the vasoactive mediators interleukin-1beta and interleukin-6. Thus, in angiotensin II-induced hypertension, bone marrow-derived AT(1) receptors limited mononuclear cell accumulation in the kidney and mitigated the chronic hypertensive response, possibly through the regulation of vasoactive cytokines.
血管紧张素 1 型受体(AT(1))的激活可导致高血压,进而引起进行性肾损伤。AT(1)受体在免疫细胞上表达,先前的研究已经确定了免疫细胞在血管紧张素 II 依赖性高血压中的作用。因此,我们通过生成具有野生型供体或缺乏 AT(1A)受体的供体(BMKO)的骨髓嵌合体,研究了免疫细胞上的 AT(1)受体在高血压发病机制中的作用。这两组在基线时的血压几乎相同,这表明免疫细胞上的 AT(1)受体对确定基线血压没有独特的贡献。相比之下,在慢性血管紧张素 II 输注的反应中,BMKO 的高血压反应增强,表明免疫细胞上的 AT(1)受体对血压升高具有保护作用。在血管紧张素 II 依赖性高血压 4 周后,BMKO 的白蛋白尿增加了 50%。两组的血管紧张素 II 诱导的肾脏病理性损伤相似。然而,在 BMKO 组中,巨噬细胞趋化因子单核细胞趋化蛋白 1 的肾表达明显增加,导致肾脏中巨噬细胞持续积聚。这种增强的单核细胞浸润到 BMKO 肾脏与血管活性介质白细胞介素-1β和白细胞介素-6 的肾表达过度有关。因此,在血管紧张素 II 诱导的高血压中,骨髓源性 AT(1)受体限制了单核细胞在肾脏中的积聚,并减轻了慢性高血压反应,这可能是通过调节血管活性细胞因子来实现的。